Eralfon - Instructions For Use, Price, Reviews, Solution Analogues

2024 Author: Rachel Wainwright | [email protected]. Last modified: 2023-12-15 07:39

Eralfon

Eralfon: instructions for use and reviews

1. 1. Release form and composition
2. 2. Pharmacological properties
3. 3. Indications for use
4. 4. Contraindications
5. 5. Method of application and dosage
6. 6. Side effects
7. 7. Overdose
8. 8. Special instructions
9. 9. Application during pregnancy and lactation
10. 10. Use in childhood
11. 11. In case of impaired renal function
12. 12. For violations of liver function
13. 13. Drug interactions
14. 14. Analogs
15. 15. Terms and conditions of storage
16. 16. Terms of dispensing from pharmacies
17. 17. Reviews
18. 18. Price in pharmacies

Latin name: Eralfon

ATX code: B03XA01

Active ingredient: epoetin alfa (Epoetin alfa)

Producer: CJSC PharmFirma SOTEX (Russia)

Description and photo update: 28.11.2018

Prices in pharmacies: from 1500 rubles.

Buy

Eralfon is an antianemic drug, a stimulator of hematopoiesis (blood formation).

Release form and composition

Eralfon is produced in the form of a solution for intravenous (i / v) and subcutaneous (s / c) administration: colorless transparent liquid [1 ml in 1 ampoule of colorless glass, 5 ampoules in a cell contour package, in a cardboard box with first opening control 1 or 2 packs. 0.3 ml / 1000 international units (IU); 0.3 ml / 2000 IU; 0.4 ml / 4000 IU; 0.5 ml / 2000 IU; 0.6 ml / 10,000 IU; 1 ml / 10,000 IU in a syringe with or without a needle protection device, in a blister strip packaging 1, 2 or 3 syringes, in a cardboard box with a first opening control of 1 or 2 packages. 0.3 ml / 2000 IU; 0.5 ml / 2000 IU; 0.6 ml / 10,000 IU; 1 ml / 10,000 IU in a syringe with or without a needle protection device, in a blister strip, 2 syringes each, in a cardboard box with a first opening control 5 packages. 0.25 ml / 2500 IU; 0.6 ml / 6000 IU; 0,8 ml / 8000 IU in a syringe with or without a needle protection device, in a blister strip of 3 syringes, in a cardboard box with a first opening control of 1 or 2 packages. 0.3 ml / 3000 IU; 0.3 ml / 5000 IU; 0.5 ml / 20,000 IU; 0.6 ml / 20,000 IU in a syringe with or without a needle protection device, in a blister strip of 1 or 3 syringes, in a cardboard box with a first opening control of 1 or 2 packages. 0.3 ml / 12,000 IU; 1 ml / 40,000 IU in a syringe with or without a needle protection device, in a blister strip packaging 1 syringe, in a cardboard box with a first opening control 1 package; in a contour acheikova package 2 or 3 syringes with a needle protection device or without it, in a cardboard box with a first opening control 1 or 2 packages; each pack also contains instructions for using Eralfon].in a contour acheikova packing of 3 syringes, in a cardboard box with a first opening control 1 or 2 packages. 0.3 ml / 3000 IU; 0.3 ml / 5000 IU; 0.5 ml / 20,000 IU; 0.6 ml / 20,000 IU in a syringe with or without a needle protection device, in a blister strip of 1 or 3 syringes, in a cardboard box with a first opening control of 1 or 2 packages. 0.3 ml / 12,000 IU; 1 ml / 40,000 IU in a syringe with or without a needle protection device, in a blister strip packaging 1 syringe, in a cardboard box with a first opening control 1 package; in a contour acheikova package 2 or 3 syringes with a needle protection device or without it, in a cardboard box with a first opening control 1 or 2 packages; each pack also contains instructions for using Eralfon].in a contour acheikova packing of 3 syringes, in a cardboard box with a first opening control 1 or 2 packages. 0.3 ml / 3000 IU; 0.3 ml / 5000 IU; 0.5 ml / 20,000 IU; 0.6 ml / 20,000 IU in a syringe with or without a needle protection device, in a blister strip of 1 or 3 syringes, in a cardboard box with a first opening control of 1 or 2 packages. 0.3 ml / 12,000 IU; 1 ml / 40,000 IU in a syringe with or without a needle protection device, in a blister strip packaging 1 syringe, in a cardboard box with a first opening control 1 package; in a contour acheikova package 2 or 3 syringes with a needle protection device or without it, in a cardboard box with a first opening control 1 or 2 packages; each pack also contains instructions for using Eralfon].5 ml / 20,000 IU; 0.6 ml / 20,000 IU in a syringe with or without a needle protection device, in a blister strip of 1 or 3 syringes, in a cardboard box with a first opening control of 1 or 2 packages. 0.3 ml / 12,000 IU; 1ml / 40,000 IU in a syringe with or without a needle protection device, in a blister strip packaging 1 syringe, in a cardboard box with first opening control 1 package; in a contour acheikova package 2 or 3 syringes with a needle protection device or without it, in a cardboard box with a first opening control 1 or 2 packages; each pack also contains instructions for using Eralfon].5 ml / 20,000 IU; 0.6 ml / 20,000 IU in a syringe with or without a needle protection device, in a blister strip of 1 or 3 syringes, in a cardboard box with a first opening control of 1 or 2 packages. 0.3 ml / 12,000 IU; 1 ml / 40,000 IU in a syringe with or without a needle protection device, in a blister strip packaging 1 syringe, in a cardboard box with a first opening control 1 package; in a contour acheikova package 2 or 3 syringes with a needle protection device or without it, in a cardboard box with a first opening control 1 or 2 packages; each pack also contains instructions for using Eralfon].1 ml / 40,000 IU in a syringe with or without a needle protection device, in a blister strip packaging 1 syringe, in a cardboard box with a first opening control 1 package; in a contour acheikova package 2 or 3 syringes with a needle protection device or without it, in a cardboard box with a first opening control 1 or 2 packages; each pack also contains instructions for using Eralfon].1 ml / 40,000 IU in a syringe with or without a needle protection device, in a blister strip packaging 1 syringe, in a cardboard box with a first opening control 1 package; in a contour acheikova package 2 or 3 syringes with or without a needle protection device, in a cardboard box with a first opening control 1 or 2 packages; each pack also contains instructions for using Eralfon].

Solution composition:

• active substance: epoetin alfa (recombinant human erythropoietin) - in 1 ampoule / 1 ml - 1000/2000/4000/10 000 IU; 1 syringe 0.25 ml - 2500 IU; in 1 syringe 0.3 ml - 1000/2000/3000/5000/12,000 IU; 1 syringe 0.4 ml - 4000 IU; 1 syringe 0.5 ml - 2000/20 000 IU; in 1 syringe 0.6 ml - 6000/10 000/20 000 IU; 1 syringe 0.8 ml - 8000 IU; in 1 syringe 1 ml - 10,000/40,000 IU;
• additional components: sodium citrate pentasequihydrate or sodium citrate dihydrate, albumin solution, citric acid monohydrate, sodium chloride, water for injection.

Pharmacological properties

Pharmacodynamics

Epoetin alfa is a glycoprotein that specifically stimulates erythropoiesis, activates mitosis and promotes the maturation of erythrocytes from erythrocyte progenitor cells. Recombinant epoetin alfa is produced in mammalian cells with a built-in gene for human erythropoietin (hematopoietin). The active substance is identical in composition, immunological and biological properties to natural human erythropoietin. The use of epoetin alfa increases hematocrit and hemoglobin (Hb) levels, improves heart function and tissue blood supply.

The most pronounced therapeutic effect of epoetin alfa is shown in the treatment of anemias caused by chronic renal failure (CRF). Against the background of prolonged use of erythropoietin for the treatment of anemic conditions, in extremely rare cases, neutralizing antibodies to it may appear with or without the appearance of partial red cell aplasia.

Pharmacokinetics

In healthy volunteers and patients with uremia after intravenous administration of epoetin alfa, the half-life (T _1/2) is 5-6 hours.

With subcutaneous injections of epoetin alfa, the level of its content in the blood increases slowly and reaches maximum values in the period from 12 to 18 hours after administration, T _1/2 can be 16-24 hours, bioavailability - 25-40%.

The substance does not accumulate in the body.

Indications for use

• anemia in chronic renal failure, including in patients on hemodialysis therapy (treatment);
• anemia in patients with multiple myeloma, chronic lymphocytic leukemia, low-grade non-Hodgkin's lymphomas (prevention / treatment);
• anemia due to anticancer therapy in patients with solid tumors (prevention / treatment);
• anemia against the background of rheumatoid arthritis (prevention / treatment);
• anemia in patients infected with human immunodeficiency virus (HIV) associated with the use of zidovudine, against a background of endogenous erythropoietin levels of less than 500 IU / ml (prevention / treatment);
• anemia in premature babies born with low body weight up to 1.5 kg (prevention / treatment);
• planned extensive surgical interventions in adult patients with an estimated blood loss of 900–1800 ml, in the absence of anemia or in the case of mild / moderate anemia, against a background of Hb concentration of 100–130 g / l - before surgery, in order to reduce the need in allogeneic blood transfusions and facilitating the restoration of erythropoiesis;
• planned major surgical interventions in patients with a hematocrit level of 33-39%, when the expected need for transfused blood exceeds the volume that can be obtained by autologous collection without prescribing epoetin alfa - before surgery, in order to facilitate collection of autologous blood and reduce the threat associated with carrying out allogeneic blood transfusions, as part of the pre-deposit program.

Contraindications

Absolute:

• uncontrolled arterial hypertension;
• partial red cell aplasia, which developed after previous treatment with any of the erythropoietins;
• the inability to receive effective anticoagulant therapy by the patient;
• severe occlusive lesions of the carotid, coronary, cerebral and peripheral arteries and their consequences, including acute cerebrovascular accident and acute and / or recent myocardial infarction (as part of a pre-deposit blood collection program before surgery);
• hypersensitivity to any of the components of Eralfon.

Relative (you must use the drug with extreme caution):

• thrombocytosis, thrombosis (in history);
• chronic liver failure;
• porphyria;
• malignant neoplasms;
• epileptic syndrome (including a history of indications);
• sickle cell anemia;
• B ₁₂ -, iron or folic deficiency states.

Eralfon, instructions for use: method and dosage

Eralfon solution is intended for intravenous and subcutaneous administration.

Treatment of anemia in patients with chronic renal failure

For adult patients on hemodialysis, Eralfon should be administered intravenously or subcutaneously at the end of the dialysis session. In case of a change in the route of administration, the drug is injected at the same dose. If necessary, make its correction (with subcutaneous administration, to achieve a similar therapeutic effect, it is required to use a dose of the solution 20–30% lower than with intravenous administration). Treatment with the drug consists of two stages: a correction phase and a maintenance phase.

In the correction phase, Eralfon is injected 3 times a week at an initial single dose of 30 IU / kg - with subcutaneous administration, or 50 IU / kg - with intravenous administration. The stage of correction continues until the optimal Hb level is reached, which is 100–120 g / l in adults, 95–110 g / l in children, and the hematocrit level is 30–35%. An assessment of these indicators is required on a weekly basis.

Dose adjustment depending on the change in the hematocrit content (the rate of its weekly increase is indicated as a percentage):

• from 0.5 to 1 - the dose is not adjusted until the desired values are achieved;
• less than 0.5 - a single dose is increased by 1.5 times;
• more than 1 - a single dose is reduced by 1.5 times;
• there is no increase or the level decreases - before increasing the dose, it is necessary to analyze the cause of drug resistance, since the degree of effectiveness of the latter depends on the optimally selected individual treatment regimen.

In the phase of maintenance therapy, in order to maintain the hematocrit at the level of 30–35%, it is recommended to reduce the dose of Eralfon used at the correction stage by 1.5 times. Further, the maintenance dose is determined individually, taking into account changes in hematocrit and Hb levels.

Children on hemodialysis treatment are prescribed Eralfon 3 times a week at an initial dose of 50 IU / kg. To achieve the optimal Hb level, a single dose may be increased by 25 IU / kg once every 4 weeks.

Maintenance dose in children, depending on body weight (the average single dose is indicated with a frequency of administration 3 times a week):

• less than 10 kg - 100 IU / kg (75-150 IU / kg);
• from 10 to 30 kg - 75 IU / kg (60-150 IU / kg);
• more than 30 kg - 33 IU / kg (30-100 IU / kg).

For adult patients at the pre-dialysis stage, Eralfon is administered subcutaneously or intravenously 3 times a week at 50 IU / kg. If necessary, a single dose is increased by 25 IU / kg once every 4 weeks. until the required Hb level is reached. The maintenance dose is 17–33 IU / kg 3 times a week.

Treatment and prevention of anemia in patients with solid tumors

For the treatment of anemia in patients with oncological diseases, Eralfon is recommended to be administered subcutaneously. The optimal Hb concentration is 120 g / l in men and women. Before starting the course, the level of endogenous erythropoietin should be established. When the concentration of erythropoietin in the serum is below 200 IU / ml, the drug is administered 3 times a week intravenously at an initial dose of 150 IU / kg or once a week subcutaneously at a dose of 40,000 IU.

If, 4 weeks after the start of treatment, an increase in Hb concentration is at least 10 g / l or an increase in the number of reticulocytes is more than 40,000 cells / μl above the initial level, the initial dose of Eralfon is left unchanged (i.v. 150 IU / kg).

If after 4 weeks of therapy the increase in the Hb level is less than 10 g / l and the increase in the number of reticulocytes is less than 40,000 cells / μl in comparison with the initial level, then over the next 4 weeks the dose is increased to 300 IU / kg 3 times a week or up to 60,000 IU once a week. When, after an additional 4 weeks, the Hb level has increased and is at least 10 g / l or the number of reticulocytes has increased by more than 40,000 cells / μl, the drug continues to be used at the same dose (300 IU / kg 3 times a week). If, after 4 weeks of treatment, the Hb concentration increased by less than 10 g / l and the increase in the number of reticulocytes was less than 40,000 cells / μl from the initial level, then during the next 4 weeks the use of Eralfon should be abandoned.

If the Hb level increases by more than 20 g / l during the month, the dose of Eralfon needs to be reduced by 25%. If the Hb level is above 120 g / l, therapy should be interrupted until its level is less than 120 g / l and then the injection of the drug should be resumed at a dose lower than the initial one by 25%.

After completing the course of chemotherapy, Eralfon should be administered for another 1 month. Serum iron concentration (or ferritin level) should be established before and during treatment, and if necessary, supplemental iron intake is recommended.

Treatment and prevention of anemia in patients with HIV infection

Before starting the course, it is required to establish the initial level of serum endogenous erythropoietin, if it is more than 500 IU / ml, the effect of drug treatment, according to research results, is unlikely.

In the correction phase, Eralfon is administered subcutaneously or intravenously 3 times a week at a dose of 100 IU / kg for 8 weeks. If, after 8 weeks of the course, a satisfactory result was not noted (the Hb level did not increase or the need for blood transfusions did not decrease), then a phased dose increase by 50-100 IU / kg 3 times a week is possible, no more than 1 time per 4 weeks. In the absence of a satisfactory result from treatment with the drug 3 times a week at a dose of 300 IU / kg, an adequate response to its further use in higher doses is unlikely.

In the phase of maintenance therapy, the prescribed dose after achieving the desired result at the stage of correction should provide a hematocrit content in the range of 30–35%, taking into account the correction of the dose of zidovudine and possible concomitant diseases of an infectious or inflammatory nature. If the hematocrit level is more than 40%, it is necessary to stop injections until this indicator drops to 36%. When resuming treatment, the dose of Eralfon should be reduced by 25% with further adjustment in order to maintain the required hematocrit. If necessary, after determining the level of serum ferritin (or serum iron), additional iron intake may be prescribed.

Treatment and prevention of anemia against the background of other diseases

In patients with multiple myeloma, chronic lymphocytic leukemia, low-grade non-Hodgkin's lymphomas, the feasibility of Eralfon therapy is determined by the inadequate production of endogenous erythropoietin against the background of anemia. When the concentration of Hb is less than 100 g / l and serum erythropoietin is below 100 IU / ml, the drug is prescribed s / c 3 times a week at a starting dose of 100 IU / kg. Hemodynamic parameters should be monitored daily and, if necessary, the dose of Eralfon should be adjusted (increase or decrease) every 3-4 weeks. If no increase in Hb level is observed against the background of using the solution in a weekly dose of 600 IU / kg, further treatment is inappropriate.

In patients with rheumatoid arthritis, the production of endogenous erythropoietin is suppressed due to the influence of an increased concentration of pro-inflammatory cytokines. In the treatment of anemia, such patients are advised to administer the drug subcutaneously 3 times a week at a dose of 50–75 IU / kg. If the Hb content increases by less than 10 g / l, after 4 weeks of therapy, the dose is increased to 150-200 IU / kg 3 times a week. Higher doses of epoetin alfa are ineffective.

For premature babies born with low body weight, starting from the sixth day of life, Eralfon is prescribed s / c at a dose of 200 IU / kg 3 times a week until the target values for Hb and hematocrit are achieved. The course of therapy should not exceed 6 weeks.

Adults participating in the autologous blood collection program prior to surgery are advised to administer Eralfon IV after donating blood. Before using the product, it is necessary to take into account all the existing contraindications to the collection of autologous blood. Before surgery, the drug should be used intravenously 2 times a week for 3 weeks at a recommended dose of 600 IU / kg. At each visit to the doctor, a portion of blood is taken from the patient (provided that the hematocrit is at least 33% and / or the hemoglobin level is at least 110 g / l) and stored for autologous transfusion.

Serum iron levels should be established before and during drug treatment. Before using epoetin alfa in the presence of anemia, it is necessary to find out what causes it. To ensure an adequate intake of iron in the body, it is required to take its preparations orally in a daily dose of 200 mg throughout the course.

For patients in the pre- and postoperative period who do not take part in the autologous blood collection program, it is recommended to use the agent in the form of subcutaneous injections at a dose of 600 IU / kg per week for 3 weeks preceding the surgical intervention: at 21, 14 and 7 th days before surgery, and on the day of surgery. If, for medical reasons, it is required to shorten the preoperative period, Eralfon is allowed to be administered daily at 300 IU / kg for 10 days before surgery, on the day of surgery and for 4 days after it. When in the preoperative period the concentration of Hb reaches 150 g / l and higher, the use of Eralfon should be discontinued. Before starting treatment, it is necessary to make sure that there is no iron deficiency, which all patients need to receive in adequate amounts throughout the course of therapy.

Syringe Directions

When using a syringe with an automatic needle guard after injection, the syringe and needle are moved back into the guard. During the preparation of the syringe for the procedure, it is necessary to avoid contact with the clamps, since the device is activated by pressing the rod up to the clamps. A pre-filled glass syringe with a safety device should be carefully inspected before injecting the drug, then, after removing the protective cap from the needle, inject in accordance with standard procedure. For the complete introduction of the entire dose, you need to press the stem with your thumb and hold it in this position for a while. The activation of the protective device will not occur until the entire dose of the agent has been injected. After completing the injection of the solution, remove the needle and release the stem, allowing the protective cover to move forward,until it protects and blocks the needle.

When using a syringe with a non-automatic needle protector, the injection is carried out according to the standard procedure. During insertion, fingers should be kept on the casing to prevent premature activation of the safety device. After completion of the injection, the protection device must be moved along the needle, the click produced will confirm the correctness of the manipulation. Keep your fingers behind the needle throughout the procedure.

Side effects

At the beginning of the course of treatment with Eralfon, the development of the following flu-like symptoms may occur: headache, drowsiness, dizziness, fever, arthralgia, myalgia.

Also, during the period of therapy, the occurrence of such side reactions from systems and organs is possible:

• hematopoietic organs: thrombocytosis; in some cases - thrombosis of an arteriovenous fistula or shunt (including patients undergoing hemodialysis treatment, with a tendency to arterial hypotension or with stenosis, aneurysm, etc.), aplasia of the erythrocyte lineage;
• cardiovascular system: dose-dependent increase in blood pressure (BP), aggravation of the course of arterial hypertension (mainly in patients with chronic renal failure); in some cases, a hypertensive crisis, a sharp increase in blood pressure, accompanied by generalized tonic-clonic seizures and symptoms of encephalopathy (confusion, headache);
• local reactions: mild / moderate soreness at the injection site, burning, hyperemia (more often developed with subcutaneous injections);
• allergic reactions: mild / moderate skin rash, itching, urticaria, eczema, angioedema;
• others: exacerbation of porphyria; complications due to a decrease in blood pressure or respiratory failure; immune responses (induction of antibody production);
• laboratory indicators: a decrease in the level of ferritin in serum, against the background of uremia - hyperphosphatemia, hyperkalemia.

Overdose

In case of an overdose of epoetin alfa, there may be an increase in unwanted side effects.

If an overdose is suspected, symptomatic therapy is performed. Bloodletting is prescribed against the background of high Hb levels.

special instructions

During the period of Eralfon therapy, it is necessary to carry out a weekly complete blood count (including determination of hematocrit, platelets, ferritin) and monitoring of blood pressure. Before and after surgery, the Hb concentration should be monitored more frequently if its baseline level was less than 140 g / L. It should be borne in mind that in the treatment of anemia, epoetin alfa is not able to replace blood transfusion, but may reduce the need for its re-appointment.

In the presence of a history of thrombotic complications and / or controlled arterial hypertension, an increase in the dose of anticoagulants and / or antihypertensive drugs may be required, respectively.

Despite the fact that epoetin alfa stimulates erythropoiesis, it is impossible to completely exclude the possibility of its effect on the growth of some types of tumors (including bone marrow neoplasms).

Preoperative increases in Hb levels may be associated with an increased risk of thrombotic complications. Before carrying out planned surgical treatment, patients need to receive effective prophylactic antiplatelet therapy. If the patient's initial Hb level is more than 150 g / l, it is not recommended to use Eralfon in the pre- and postoperative period.

Against the background of chronic renal failure, chronic heart failure or clinically severe coronary artery disease (IHD) in adult patients, the Hb content should not exceed 100–120 g / l.

Before starting therapy, it is necessary to exclude potential causes of an inadequate response to epoetin alfa, which may include: lack of iron, cyanocobalamin and folic acid, severe poisoning with aluminum salts, concomitant infections, trauma, inflammation, hemolysis, latent bleeding, bone marrow fibrosis of various etiologies. If necessary, adjust the treatment.

Before you start using Eralfon, you should assess the iron stores in the body. In most cases, in cancer and HIV-infected patients, as well as in patients with chronic renal failure, the plasma concentration of ferritin decreases simultaneously with an increase in hematocrit. The ferritin content must be monitored throughout the course of therapy. When its level is below 100 ng / ml, oral administration of iron preparations is recommended - for adults, 200–300 mg per day, for children, 100–200 mg. In premature infants, treatment with oral iron preparations at a daily dose of 2 mg should be started as early as possible. Patients who donate autologous blood and are in the pre- or postoperative period must also provide an adequate intake of iron at a dose of 200 mg per day.

The use of epoetin alfa in predialysis patients, according to the available data, does not lead to an acceleration of the progression of chronic renal failure. During a hemodialysis session, due to an increase in hematocrit, it is often necessary to increase the dose of heparin. In the case of inadequate heparinization, the threat of blockage of the dialysis system, thrombosis of the vascular access is aggravated, mainly in patients with a tendency to hypotension or with complications of arteriovenous fistula (aneurysm, stenosis, etc.). Thrombosis prophylaxis is recommended for patients from this risk group.

Against the background of chronic renal failure in women of reproductive age, when using Eralfon for the treatment of anemia, the likelihood of resumption of menstruation increases. Patients during the use of the drug should take into account the possibility of pregnancy, and use reliable methods of contraception before starting the administration. In the course of experimental studies on animals, no teratogenic effect was detected with intravenous injections of Eralfon in doses less than 500 U / kg per day. When using the drug in higher doses, there was a statistically insignificant, weak decrease in fertility.

Since Eralfon may demonstrate a more pronounced effect, it should be used in doses not exceeding the dose of recombinant erythropoietin prescribed during previous therapy. No dose adjustment is made during the first two weeks by assessing the dose / response ratio. In the future, it is possible to reduce or increase the dose according to the above scheme.

Influence on the ability to drive vehicles and complex mechanisms

During therapy, patients with chronic renal failure to determine an effective maintenance dose, care must be taken when driving vehicles or other complex mechanisms due to the aggravated risk of increased blood pressure at the beginning of the course of treatment.

Application during pregnancy and lactation

Appropriate controlled studies of the use of erythropoietin during pregnancy and lactation have not been conducted. It is allowed to use Eralfon during pregnancy only when the expected benefits from drug therapy for a woman significantly exceed the risk to the fetus.

It is not known whether epoetin alfa penetrates into breast milk, therefore, if it is necessary to use an antianemic drug during lactation, the infant should be transferred to artificial feeding.

Pediatric use

In pediatric practice, the use of Eralfon is possible according to the prescription of the attending physician according to the indications.

With impaired renal function

Patients with chronic renal failure should be monitored for serum electrolyte levels. In the presence of chronic renal dysfunction, correction of anemia can lead to improved appetite and increased absorption of potassium and proteins. In this connection, it may be necessary to periodically adjust the parameters of dialysis in order to maintain the levels of creatinine, urea and potassium within the normal range.

For violations of liver function

In the presence of chronic liver failure, the drug should be used with caution. In patients with hepatic insufficiency, a slower biotransformation of epoetin alfa and a significant increase in the course of erythropoiesis may be observed. There is no information confirming the safety of using Eralfon in this category of patients.

Drug interactions

Established pharmaceutical incompatibility of Eralfon solution with solutions of other drugs.

Epoetin alfa reduces the content of cyclosporine in the blood due to an increase in the degree of its connection with erythrocytes (a dose adjustment of cyclosporine may be required).

Analogs

Eralfon's analogs are Aeprin, Binocrit, Rapoetin-SP, Epocrin, Eprex, etc.

Terms and conditions of storage

Store out of the reach of children at 2–8 ° C.

The shelf life of Eralfon in ampoules is 2 years, in syringes - 3 years.

Terms of dispensing from pharmacies

Dispensed by prescription.

Reviews about Eralfon

On medical sites, reviews about Eralfon are mostly positive. The effectiveness of the use of the drug for the prevention and treatment of anemia is noted both in adult patients and in children, especially premature babies born with low weight. Most reviews indicate a satisfactory result from the use of Eralfon for the treatment of anemia against the background of chronic renal failure, rheumatoid arthritis, during surgery. Many people note the good tolerance of the drug.

In rare cases, the appearance of adverse reactions in the form of a flu-like condition, headache and drowsiness is mentioned.

Price for Eralfon in pharmacies

The price of Eralfon, solution for intravenous and subcutaneous administration can be:

• syringe 2000 IU / 0.3 ml; 6 pcs. - 3500 rubles;
• syringe 3000 IU / 0.3 ml; 6 pcs. - 8400 rubles;
• syringe 2000 IU / 0.5 ml; 6 pcs. - 3500 rubles;
• syringe 10,000 IU / 0.6 ml; 2 pcs. - 4500 rubles;
• syringe 10,000 IU / 1 ml; 1 PC. - 2600 rubles; 12 pcs. - 12 600 rubles;
• syringe 40,000 IU / 1 ml; 1 PC. - 19,200 rubles.

Eralfon: prices in online pharmacies

Drug name Price Pharmacy

Eralfon 10000 IU solution for intravenous and subcutaneous administration 1 ml 1 pc. RUB 1,500 Buy

Eralfon 10000 IU solution for intravenous and subcutaneous administration 0.25 ml 6 pcs. 1600 RUB Buy

Eralfon 2000 IU solution for intravenous and subcutaneous administration 1 ml 10 pcs. 1600 RUB Buy

Eralfon 2000 IU solution for intravenous and subcutaneous administration 0.5 ml 6 pcs. 1600 RUB Buy

Eralfon 1000 IU solution for intravenous and subcutaneous administration 0.3 ml 6 pcs. 2699 RUB Buy

Eralfon i / v and s / c 10000me 1ml n1 RUB 2710 Buy

Eralfon 2500 IU solution for intravenous and subcutaneous administration with a needle protection device 0.25 ml 6 pcs. 2900 RUB Buy

Eralfon solution for intravenous and subcutaneous injection. 2000ME 0.5ml 6 pcs. 3655 RUB Buy

Eralfon 3000 IU solution for intravenous and subcutaneous administration 0.3 ml 6 pcs. RUB 8327 Buy

Eralfon solution for intravenous and subcutaneous injection. 3000ME 0.3ml 6 pcs. RUB 8697 Buy

Eralfon 40,000 IU solution for intravenous and subcutaneous administration 0.3 ml 3 pcs. RUB 12,000 Buy

Eralfon 40,000 IU solution for intravenous and subcutaneous administration 1 ml (40,000 IU) 1 pc. 13930 RUB Buy

Eralfon 4000 IU solution for intravenous and subcutaneous administration 0.4 ml 6 pcs. RUB 17250 Buy

See all offers from pharmacies

Maria Kulkes Medical journalist About the author

Education: First Moscow State Medical University named after I. M. Sechenov, specialty "General Medicine".

Information about the drug is generalized, provided for informational purposes only and does not replace the official instructions. Self-medication is hazardous to health!